Close
Help





JOURNAL

Biomarkers in Cancer

Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells

Submit a Paper


Biomarkers in Cancer 2015:Suppl. 2 25-32

Review

Published on 15 Dec 2015

DOI: 10.4137/BIC.S29326


Further metadata provided in PDF



Sign up for email alerts to receive notifications of new articles published in Biomarkers in Cancer

Abstract

Acquired resistance to targeted inhibitors remains a major, and inevitable, obstacle in the treatment of oncogene-addicted cancers. Newer-generation inhibitors may help overcome resistance mutations, and inhibitor combinations can target parallel pathways, but durable benefit to patients remains elusive in most clinical scenarios. Now, recent studies suggest a third approach may be available in some cases—exploitation of oncogene over-expression that may arise to promote resistance. Here, we discuss the importance of maintaining oncogenic signaling at “just-right” levels in cells, with too much signaling, or oncogene overdose, being potentially as detrimental as too little. This is highlighted in particular by recent studies of mutant-BRAF in melanoma and the fusion kinase nucleophosmin–anaplastic lymphoma kinase (NPM–ALK) in anaplastic large cell lymphoma. Oncogene overdose may be exploitable to prolong tumor control through intermittent dosing in some cases, and studies of acute lymphoid leukemias suggest that it may be specifically pharmacologically inducible.



Downloads

PDF  (1.72 MB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)

XML





Quick Links


New article and journal news notification services